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Abstract
Streptococcus mutans is one of the principal agents of caries formation mainly, because of
its ability to form biofilms at the tooth surface. Bacteriophages (phages) are promising anti-
microbial agents that could be used to prevent or treat caries formation by S.mutans. The
aim of this study was to isolate new S.mutans phages and to characterize their antimicro-
bial properties. A new phage, ɸAPCM01, was isolated from a human saliva sample. Its
genome was closely related to the only two other available S.mutans phage genomes,
M102 and M102AD. ɸAPCM01 inhibited the growth of S.mutans strain DPC6143 within
hours in broth and in artificial saliva at multiplicity of infections as low as 2.5x10-5. In the
presence of phage ɸAPCM01 the metabolic activity of a S.mutans biofilm was reduced
after 24 h of contact and did not increased again after 48 h, and the live cells in the biofilm
decreased by at least 5 log cfu/ml. Despite its narrow host range, this newly isolated S.
mutans phage exhibits promising antimicrobial properties.
Introduction
The microbiome of the human oral cavity is composed of numerous and diverse bacteria,
archaea, eukaryotes and viruses [1–3]. Dental caries arise as a result of an ecological imbalance
of metabolic activities in the stable oral microbiome. Dental caries is one of the most prevailing
and persistent disease in the human population, despite the availability of various prophylactic
options. Streptococcus mutans is a Gram-positive, coccus-shaped, non-motile and facultative
anaerobic bacterium which is naturally present in the human mouth. It is an opportunistic
pathogen and the principal etiological agent of dental decay in humans. S.mutans is able to
adhere to the tooth surface in biofilm communities that contribute to dental plaque and favour
the progression of dental disease [4, 5]. Within the dental plaque, S.mutans contributes greatly
to the composition of the biofilm matrix, especially by producing abundant exopolysaccharides
(EPS) [6]. S.mutans pathogenicity also results from its acidogenicity in the presence of dietary
sucrose and its concomitant acid tolerance, both of which support changes in the ecology of
the dental plaque by selecting for a cariogenic flora, increasing the probability of enamel
demineralization and eventually caries formation [7]. When established as a biofilm, microbial
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communities are less sensitive to conventional antimicrobial interventions and, in any event,
antibiotics are not favoured as a means of controlling or preventing caries.
Bacteriophage (phage) therapy is increasingly considered as a potential alternative to antibi-
otic treatments [8]. Phages are bacterial viruses that can attack and kill a target bacterium
within minutes of infection. They are self-replicating and generally only target a narrow range
of bacterial strains of the same species. Phages have been used in clinical settings for decades
and are now accepted to be effective for the control of pathogenic bacteria in food [9]. Com-
mercial phage cocktails, such as ListShieldTM and LISTEXTM P100, are used against Listeria
monocytogenes in the food industry and have obtained Generally Recognized As Safe (GRAS)
status from the FDA [10]. While phages have been extensively used in some countries of East-
ern Europe for clinical purposes, there are still no approved phage treatments in the Western
world for clinical use [10]. However, promising research is being conducted on phages to treat
bacterial pathogens such as Pseudomonas aeruginosa [11], enteroaggregative Escherichia coli
[12], Clostridium difficile [13] and methicillin-resistant Staphylococcus aureus [14]. By discov-
ering new phages effective against pathogenic bacteria, it is possible to develop alternative treat-
ment methods to antibiotics. A few studies exist regarding the use of phages for curing dental
infections with various pathogens such as Enterococcus faecalis [15], Fusobacterium nucleatum
[16] and P. aeruginosa [17]. To our knowledge, no study has been dedicated to the use of
phages to control S.mutans growth and biofilm formation. Relatively little is known about S.
mutans phages. To date only two S.mutans phage genomes, M102 and M102AD, are available
in public databases [18, 19]. Two other S.mutans phages, e10 and f1, have previously been iso-
lated and tested for their host range and morphology, without being sequenced [20]. The aim
of the current study was to isolate and characterize new S.mutans phages from saliva samples,
and to test their efficacy in reducing S.mutans growth and biofilm formation for potential
future application as antimicrobial agents.
Materials and Methods
Strains and culture conditions
S.mutans strains (Table 1) were grown overnight in BHI broth (Oxoid, Basingstoke, United
Kingdom) at 37°C under aerobic conditions. All strains originated from the collection of Moor-
epark Food Research Centre (Ireland). Strain serotypes were checked using a PCR method
described previously [21] (Table 1).
Human subject enrolment
Subject recruitment and enrolment were approved by the Clinical Research Ethics Committee
of the Cork Teaching Hospitals (protocol no. APC052). All subjects completed a questionnaire
demonstrating their willingness to participate in the study. All subjects were healthy adults
without known oral health problems. A minimum of 3 ml of saliva was collected in the morn-
ing before breakfast prior to any oral hygiene practices, and the saliva was analysed within 2 h
after collection. A total of 85 samples were collected.
Phage isolation from human saliva
One millilitre of saliva was centrifuged at 8000xg for 10 min, before being sterilised using
0.45 μm filters. Saliva filtrates were kept at 4°C. For each sample, 100 μl of saliva filtrate were
mixed with 200 μl of bacterial overnight culture, and incubated for 20 min at 37°C. The indica-
tor S.mutans strains used were DPC6143, DPC6144, DPC6145, DPC6150, DPC6151 and
DPC6152 (Table 1). The filtrate-bacteria mixture was then added to 3 ml of soft BHI agar
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(0.5% agar w/v) containing 10 mM CaCl2, and overlaid on top of a BHI agar plate. Plates were
incubated for a minimum of 24 h at 37°C or until plaques could be detected.
Electron microscopic analysis
Phage lysates were purified on a caesium chloride gradient by ultracentrifugation, and were
dialyzed against phage buffer (20 mM Tris-HCl [pH 7.2], 10 mM NaCl, 20 mMMgSO4) over-
night at 4°C. Negative staining of phages and transmission electron microscopic analysis were
as previously described [22].
One-step growth curve
A one-step growth experiment was performed in triplicate to assess the burst size, and latency
and rise phases of phage ɸAPCM01 using a method previously described [22] with the follow-
ing modifications. Incubations were performed in BHI broth supplemented with 10 mM
CaCl2, at 37°C. A multiplicity of infection (MOI) of 1 was used.
Efficiency of lysogeny
Efficiency of lysogeny was assessed as previously described [23]. Briefly, 100 μl of 1010 pfu/ml
phage lysate were spread onto BHI agar plates. An overnight culture of S.mutansDPC6143
strain was diluted by serial 1:10 dilutions. For 10−4 to 10−7 dilutions, 100 μl were mixed with
4 ml of sloppy BHI agar (0.5% agar) supplemented with 10 mM CaCl2, and overlaid onto
phage seeded plates and phage-free control plates. The plates were incubated at 37°C for 24 h.
Cfu numbers were count on countable plates, considering that the colonies growing on phage
seeded plates were all lysogens. The percentage of efficiency of lysogeny was calculated as
Table 1. Streptococcusmutans strains used in this study.
Strain
No.
Origin Serotype Source and reference
DPC6143 e
DPC6144 e
DPC6145 c
DPC6150 c
DPC6151 c
DPC6152 c
DPC6153 Dental saliva isolate from University College Cork dental
hospital
c Culture collection of Moorepark Food Research Centre (Ireland)
[48]
DPC6154 c
DPC6155 c
DPC6156 c
DPC6157 c
DPC6158 c
DPC6159 e
DPC6160 c
DPC6161 c
DPC6162 Carious dentine e Type strain NCTC10449
DPC6543 NA c University of Toronto
NA: not available
doi:10.1371/journal.pone.0138651.t001
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follows: (cfu on phage seeded plates / cfu on phage-free control plates) x 100. All experiments
were performed in triplicate.
Bacterial challenge and artificial saliva assays
Bacterial challenge and kill-curve assays were performed to determine the effect of different
MOI’s of phage on S.mutans survival. An overnight culture of S.mutansDPC6143 strain was
diluted in 2× GM17 broth (Oxoid) containing 20 mM CaCl2 to reach 10
4 cfu/ml. The wells of a
96-well microplate were filled with 100 μl of the diluted culture. Serial 1:10 dilutions of the
phage lysate were performed in phage buffer. The eight wells of each column of the 96-well
microplate containing the diluted culture were filled with 100 μl of the same phage dilution.
The range of MOI’s tested was between 2.5x10-5 and 2.5x102. One column of the plate con-
tained positive control wells with only 100 μl of the diluted S.mutans culture and 100 μl of
phage buffer. Another column contained only 100 μl of 2× GM17 broth and 100 μl of phage
buffer. The plate was incubated at 37°C for 18 h. Optical density (OD600nm) measures were
taken and a Student’s t-test was performed to assess significance (GraphPad, Prism, version
5.03). Bacterial counts were performed in triplicate for each condition tested using the enumer-
ation miniaturized method described previously [24].
Kill-curves were performed as described for the bacterial challenge assay, with OD600nm
measures recorded every 15 min using an MWGt Sirius HT plate reader (BIO-TEK1 Instru-
ments, USA).
The action of phages on S.mutansDPC6143 strain was also tested in artificial saliva [25]
supplemented with 1% sucrose. An overnight culture of S.mutansDPC6143 strain was centri-
fuged at 8000×g for 10 min at room temperature. The supernatant was discarded and the pellet
was resuspended in the same volume of 2x artificial saliva. The same method as for the bacte-
rial challenge described above was applied to assess the action of phage against S.mutans in
artificial saliva.
Biofilm assays
Two 96-well plates were filled as followed. Each well was filled with 200 μl of BHI broth inocu-
lated at 1% with an overnight culture of strain DPC6143. The plates were incubated at 37°C for
48 h to allow the biofilm to form. Broth containing planktonic cells was removed, being careful
not to disturb the cells attached to the wells. 100 μl of 2× BHI broth containing 20 mM CaCl2
and 100 μl of lysate dilutions as describe above were added to each well. Phage lysate concen-
trations from 102 to 109 phage per well were tested, with each phage concentration being tested
in 8 wells of the plate. The positive and negative controls were performed as described above.
One plate was incubated at 37°C for 24 h and the other at 37°C for 48 h. After incubation, the
wells were emptied carefully and gently washed with phosphate buffered saline. A colorimetric
assay using XTT and menadione as previously described [26] was performed to assess the met-
abolic activity of S.mutans biofilm after phage treatment. Bacterial counts were performed in
triplicate for each condition tested. Briefly, biofilms were detached from the wells by thorough
mixing by pipetting with 200 μμl maximum recovery diluent (Oxoid), and counts were carried
out following the enumeration miniaturized method [24].
DNA extraction and genome sequencing
DNA was extracted from the CsCl purified fractions [22]. Briefly, 400 μl of the CsCl purified
fraction were treated with 6 U Ambion1 TURBOTM DNase (Life technologies, USA). After
DNase treatment, 4 μl of proteinase K (20mg/ml) and 30 μl of 10% SDS were added and fol-
lowed by an incubation step of 1h at 56°C. Another incubation step of 10 min at 65°C followed
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after the addition of 70 μl 5 M NaCl and 100 μl of phage lysis buffer (4.5 M guanidine thiocya-
nate, 44 mM sodium citrate [pH 7.0], 1% sarkosyl, 72 μl 2-mercaptoethanol). DNA was then
extracted and purified using phenol:chloroform:isoamyl alcohol (25:24:1, Sigma-Aldrich,
Saint-Louis, USA), and precipitated with ice-cold ethanol. DNA samples were sent to GATC
(Konstanz, Germany) for whole phage genome sequencing using an Illumina HiSeq 2500
sequencer with 2x100 bp read length. The reads generated by the Illumina instrument were
assembled at GATC.
In silico genome analysis
Protein-encoding open reading frames (ORFs) were predicted using Glimmer [27] and the
RAST server [28]. Initial functional annotation of the ORFs and percentage amino acid identi-
ties were determined using BLASTP [29]. Phylogenetic trees were constructed using strepto-
coccal endolysin amino acid sequences which gave the highest possible identity percentage
with endolysins in phage ɸAPCM01 genome. The evolutionary history was inferred by using
the Maximum Likelihood method based on the JTT matrix-based model [30] in MEGA 6 [31].
The bootstrap consensus tree inferred from 1000 replicates was taken to represent the evolu-
tionary history of the taxa analysed [32]. Branches corresponding to partitions reproduced in
less than 50% bootstrap replicates were collapsed. Initial tree(s) for the heuristic search were
obtained by applying the Neighbor-Joining method to a matrix of pairwise distances estimated
using a JTT model.
Accession number
The complete genome sequence of ɸAPCM01 has been deposited in GenBank under accession
number KR153145.
Results
Morphology, host range, population dynamics, and lysogeny
Given the potential of phage therapy, a screening of 85 saliva samples was performed to isolate
S.mutans phage. A single S.mutans phage, ɸAPCM01, was isolated from one saliva sample.
ɸAPCM01 belongs to the (small-isometric headed) Siphoviridae family with B1 morphology as
shown by electron microscopy (Fig 1). The head diameter was 54.6 ± 1.0 nm (n = 7) and the
length of the non-contractile and flexible tail was 278.0 ± 9.7 nm (n = 7). Small baseplate struc-
tures (width: 16.1 ± 0.8 nm [n = 7]) without further appendices or fibers were visible at the dis-
tal end of the tails (tail width: 11.5 ± 0.4 nm [n = 7]). Of the 17 S.mutans strains tested
ɸAPCM01 targeted only strain DPC6143.
A one-step growth curve was performed to assess the population dynamics of ɸAPCM01 in
the presence of S.mutans strain DPC6143. ɸAPCM01 had a latent period of 60 min and a rise
phase of 60 min before reaching the plateau phase (Fig 2). The burst size was calculated as
44.2 ± 9.8 phage particles.
Lysogeny of phage ɸAPCM01 was assessed against S.mutans strain DPC6143. The numbers
of bacteria on phage seeded plates and on phage-free control plates were 5.7 ± 0.2 and
9.3 ± 0.09 log cfu/ml, respectively. This gave a mean efficiency of lysogeny of 0.027 ± 0.007%.
Bacterial challenge
The ability of ɸAPCM01 to reduce or prevent the growth of S.mutansDPC6143 was assessed
after 18 h of contact with the phage at MOI’s ranging from 2.5x10-5 to 250 (Fig 3A). A signifi-
cant decrease in OD600nm of at least 2-fold between the control culture and the cultures with
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added phages was observed for all the tested MOI’s (p-value<0.001). This indicates that the
phage was efficient even at a low MOI. This was confirmed by a decrease of at least 5.6 log
cfu/ml between the control culture and the cultures with added phages at MOI’s smaller than
2.5x10-3 (Fig 3A). At MOI’s higher than 2.5x10-2 no colonies could be detected (detection
threshold of 20 cfu/ml). ɸAPCM01 prevented the growth of S.mutans DPC6143 at MOI’s
higher than 2.5x10-2 or reduced its growth at lower MOI’s.
Kill curves confirmed this result and indicated that S.mutansDPC6143 was inhibited by
ɸAPCM01 at an early stage of growth (Fig 3B). At MOI’s higher than 10−2, no growth occurred
as OD600nm values remained the same as the sterile medium OD600nm values during the entire
incubation period. At MOI’s equal to, or less than, 10−3, some growth initially occurred but the
OD declined after 7 to 10 hours of incubation.
The lytic activity of ɸAPCM01 against S.mutans DPC6143 strain was also assessed in artifi-
cial saliva (Fig 3C). The OD600nm decreased by at least 1.5 fold compared to the control culture
without phage. Bacterial counts revealed that a significant reduction of about 3.6 log cfu/ml
(p-value<0.05) was only observed between the highest tested MOI and the control. Even if the
decrease was less dramatic in artificial saliva than in culture broth, the phage could still reduce
S.mutans DPC6143 growth in artificial saliva.
Fig 1. Transmission electronmicrograph of phage ɸAPCM01, stained with uranyl acetate.
doi:10.1371/journal.pone.0138651.g001
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Action of phage against biofilms
Phage ɸAPCM01 was tested against 48 h-attached S.mutans DPC6143 cells in 96-well plates
(Fig 4). After phage treatment, the metabolic activity of the biofilm was assessed using XTT
assays and the numbers of live cells were quantified by bacterial counts. With initial doses
equal to or higher than 102 pfu/well, ɸAPCM01 significantly reduced the biofilm activity
within 24 h of contact (p-value<0.001, Fig 4A). At doses ranging from 105 to 109 pfu/well,
phage ɸAPCM01 completely inhibited the biofilm metabolic activity as shown by OD492nm val-
ues close to 0.2, the OD value of the medium alone. At phage doses between 102 and 104 pfu/
well, OD492nm values were lower compared to the control but high enough to indicate residual
metabolic activity of S.mutans. At these doses, phage ɸAPCM01 could reduce the biofilm but
not completely disrupt it. Bacterial counts confirmed the reduction of the biofilm biomass due
to phage action after 24 h of contact (Fig 4B). A difference of at least 5 log cfu/ml was notice-
able between the control biofilm and the biofilm in the presence of phage doses higher than
105 pfu/well (Fig 4B). A difference of 1, 1.8 and 3.5 log cfu/ml was measured between the con-
trol and the biofilm at phage doses of 102, 103 and 104 pfu/well, respectively (Fig 4B).
After 48 h of contact with phage ɸAPCM01, the biofilm metabolic activity measured by
XTT was significantly reduced at phage doses of 103, 104 and 106 to 109 pfu/well compared to
the 24 h-incubation step (p-value<0.05) (Fig 4A). For these doses, OD492nm was close to the
OD492nm of the medium. At phage doses of 10
2 and 105 pfu/well, no significant changes in the
OD492nm values were observed after 48 h of contact with phage compared to the 24 h-incuba-
tion step, indicating the absence of biofilm development. At phage doses ranging from 106 to
109 pfu/well, no significant differences in the number of bacterial cells between 24 h and 48 h
of contact with the phage were noticeable (p-value>0.05, Fig 4B). This indicated that phage
ɸAPCM01 is able to control the growth of the S.mutans biofilm. An increase of 0.6 log cfu/ml
Fig 2. One-step growth curve of phage ɸAPCM01 with S.mutans strain DPC6143 in BHI broth at 37°C. Three independent experiments were carried
out. Error-bars indicate standard deviation.
doi:10.1371/journal.pone.0138651.g002
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at a phage dose of 104 pfu/well was visible (p<0.05) after 48 h. A decrease of 0.7 log cfu/ml at
phage doses of 105 and 103 pfu/well was also noticeable (Fig 4B).
Genome features and comparison with S.mutans phage M102 and
M102AD genomes
The complete genome size of phage ɸAPCM01 is 31,075 bp with a G-C content of 39%. A total
of 37 ORFs were identified on the same strand and 23 could be assigned a putative function.
No tRNA encoding regions were found in ɸAPCM01’s genome. The ɸAPCM01 genome com-
pares closely with two other S.mutans phage genomes and is organized into the following func-
tional modules: DNA packaging, morphogenesis, lysis, and DNA replication and
recombination (Fig 5). ɸAPCM01 shares 85% identity with M102 and M102AD at the nucleo-
tide level. However, some discrepancies in the number of ORFs exists between the three
phages. ORF31, encoding a protein of unknown function, is only present in the ɸAPCM01
genome while four ORFs which are present in the other phage genomes (M102 ORF34,
ORF37, ORF40, ORF41) are missing in ɸAPCM01 (Fig 5). All these ORFs are located in the
replication module and encode proteins of unknown function.
The maximum identity at the amino acid level is 99% (ORF29, small sub-unit terminase)
(Table 2). Twenty and 22 ORFs out of 37 (54% and 59% of ORFs, respectively) from
ɸAPCM01 share more than 90% identity at the amino acid level with M102AD and M102,
respectively. ORF29 is also close to ORF30 of phage M102 with 93% identity at the amino acid
level; this ORF is absent fromM102AD genome.
Comparison of phage ɸAPCM01 endolysins to other streptococcal
phage endolysins
Phages M102 and M102AD endolysins (ORF19 and ORF20) were shown to be 100% identical
and to share similarity with other streptococcal endolysins [18]. Interestingly, ORF19 and
ORF20 of ɸAPCM01 are not identical to the corresponding ORFs of phages M102 and
M102AD, and share 93.7% and 88.3% identity at the amino acid level, respectively (Table 2). S.
mutans phage endolysins were then compared to other streptococcal endolysins which gave
the closest BLAST identity values, and a phylogeny of these phages was established based on
ORF19 (Fig 6A) and ORF20 (Fig 6B). In both cases, S.mutans phages constitute a distinct
group from the other Streptococcus species. Based on ORF19 phylogeny, S.mutans phages are
closer to S. agalactiae phage than to other streptococcal phages (Fig 6A). The phylogeny based
on ORF20 could not relate S.mutans phages to any particular Streptococcus species (Fig 6B).
Discussion
S.mutans is the leading cause of dental caries worldwide and is considered to be the most cari-
ogenic of all of the oral streptococci. Very little is known about S.mutans lytic phages. To our
knowledge only two S.mutans phages, M102 and M102AD, have been sequenced to date [18,
19]. Phage M102 was isolated in 1988 in France [33], and M102AD came from a M102 batch
Fig 3. Effect of phage ɸAPCM01 on a growing culture of S.mutans DPC6143. (a) Phage activity was
assessed by OD600nm measures after 18 h of contact in BHI broth at 37°C. Experiments were performed in a
96-well microplate, and each condition was tested in 8 wells of the microplate. Enumerations were performed
in triplicate for each tested MOI (x), with a detection threshold of 20 cfu/ml. (b) Killing curves were assessed
by OD600nm measures every 15 min for 18 h at MOI of 2.5x10
-5 (), 2.5x 10−4 (■), 2.5x 10−3 (□), 2.5x 10−2 (◆),
0.25 (), 2.5 (☓), 25 (▲), 250 (△), no phage (●), and sterile medium (●). (c) Phage activity was assessed by
OD600nm measures and by bacterial counts (x) performed in triplicate after 18 h of contact in artificial saliva.
MOI: multiplicity of infection; AS: sterile artificial saliva. Error-bars indicate standard deviation. ***p<0.001.
doi:10.1371/journal.pone.0138651.g003
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kept at the University of Maryland which proved to be genetically different from the original
phage M102 after genome comparison of the two phages [18]. Two other S.mutans phages
have also been partially characterized in the University of Maryland, phages e10 and f1 [20]. A
paper from the late 70’s also relates the presence of prophage inducible with mitomycin C in
the genome of some S.mutans strains [34]. The scarcity of data on S.mutans phages is proba-
bly due to the difficulty to isolate phages from oral cavity samples. In the current study, only
one phage, ɸAPCM01, was isolated from screening 85 saliva samples. Two other studies aiming
at isolating phages against oral pathogens failed to isolate S.mutans phages [35, 36]. This could
possibly be due to the low frequency of these phages in nature or, more probably, to their nar-
row host range. ɸAPCM01 isolated in the present study only targeted S.mutans strain
DPC6143 out of the 17 tested strains. The fact ɸAPCM01 targets this strain is of importance as
this strain is serotype e, which is the second more present S.mutans serotype in the oral cavity
after serotype c [37]. Phages M102, M102AD, e10 and f1 also proved to have a narrow host-
range. In addition, these phages appear to be serotype-specific, although not all strains of the
same serotype are sensitive to a given phage [18, 20], which was the case for ɸAPCM01. Indeed,
the strain targeted by ɸAPCM01 was serotype e, and other serotype e strains tested in the pres-
ent study were not sensitive to the phage. The sensitivity to phage ɸAPCM01 of other S.
mutans strains, especially of serotype c and e, should be examined to further elucidate this
Fig 4. Effect of phage ɸAPCM01 on a 48 h-biofilm formed by S.mutansDPC6143, after 24 h (■) and 48 h (■) of contact between phage and biofilm.
(a) Biofilm metabolic activity was assessed by OD492nm measures after treatment with XTT supplemented with menadione. Experiments were performed in
96-well microplates, and each condition was tested in 8 wells of the microplate. (b) Bacterial counts in biofilms were performed in triplicate after contact with
the phage. *p<0.05; **p<0.01; ***p<0.001. Error-bars indicate standard deviation.
doi:10.1371/journal.pone.0138651.g004
Fig 5. Genomic organization of ɸAPCM01 compared with that of phagesM102 and M102AD. Each arrow represents an ORF, with the colour
representing the putative function of the encoded protein indicated on the right. Percent amino acid identity between adjacent genomes is colour coded as
outlined to the left.
doi:10.1371/journal.pone.0138651.g005
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aspect. Adsorption of M102 phage to S.mutans cells depends on the type of the glucose side
chain of the rhamnose-glucose-polysaccharides which constitute the receptor for phage M102
[38]. Moreover CRISPR sequences matching the S.mutans phage M102 genome were detected
in some S.mutans strains, indicating a bacterial resistance mechanism to this particular type of
phage [39, 40]. Other phage resistance systems also exist and are frequently discovered, like the
recent bacteriophage exclusion system BREX [41]. All these factors may make it more difficult
to find appropriate S.mutans strains with which to isolate virulent phages.
Like the four other reported S.mutans phages, ɸAPCM01 belongs to the Siphoviridae fam-
ily. Its head and tail dimensions are in accordance with that of the other S.mutans phages [18,
20]. The ɸAPCM01 genome (31,075 bp) is slightly smaller than that of phage M102 (31,147
bp) [19] and bigger than that of phage M102AD (30,664 bp) [18]. ɸAPCM01 displays 85%
nucleotide identity with M102 and M102AD and differs in that it has a reduced number of
ORFs, albeit with an additional ORF31 specific to its genome. None of its predicted proteins
are identical to those of the two previously sequenced phages. The fact that this new S.mutans
phage is so closely related to existing S.mutans phage begs the question of the origin and evolu-
tion of these phages, and of the population structure. As observed for phage M102AD, it seems
Fig 6. Molecular phylogenetic analysis by Maximum Likelihoodmethod of endolysins in S.mutans phage ɸAPCM01.Comparison of ORF19 (a) and
ORF20 (b) of ɸAPCM01 to other endolysins in streptococcal phages. Numbers indicate branches support based on 1000 bootstrap replications.
doi:10.1371/journal.pone.0138651.g006
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that the evolution of phage ɸAPCM01 genome is due to point mutations, and to the deletion
and acquisition of genes [18], with no certainty regarding the frequency and nature of events
causing those modifications. As the number of available S.mutans phage genomes is so limited
a phylogenetic explanation of these events is not yet possible. We attempted to compare S.
mutans phages to other phages by comparing their endolysins (ORF19 and ORF20). The
ɸAPCM01 endolysin encoded by ORF19 is related to endolysins from different S. agalactiae
phages. This is congruent with the observation previously made for phage M102AD where the
endolysin shares 49% of its amino acids with S. agalactiae phage B30 endolysin [18]. An
increased effort in isolating and sequencing more S.mutans phages will be required for a better
understanding of the phage population structure, taxonomy and evolution [42]. The closeness
of these three phage genomes isolated in different countries and almost 30 years apart strongly
suggests an evolution from a common ancestor, and the existence of a cohesive population of
S.mutans phages where genetic modification events occur at a very low rate.
Phage therapy is increasingly considered as a viable alternative for the treatment and control
of pathogenic bacteria [43]. To date, the antimicrobial potential of S.mutans phage has not
been extensively studied. In this study we tested the ability of ɸAPCM01 to reduce S.mutans
growth and biofilm formation. Phage ɸAPCM01 was proven to be highly lytic with a burst size
of ~44 against S.mutans strain DPC6143. Phage ɸAPCM01 also showed a lack of lysogenic
properties with an efficiency of lysogeny of less than 0.03%, confirmed by the absence of a
lysogeny module in its genome. If the colonies growing on phage-seeded plates were consid-
ered as bacteriophage-insensitive mutants (BIMs) [44], the lysogeny assay could also indicate
that the frequency of BIMs is extremely low (less than 0.03%) in the presence of ɸAPCM01.
These criteria make phage ɸAPCM01 a suitable candidate for phage therapy. ɸAPCM01 effi-
ciently reduced the growth of S.mutans by at least 5 log cfu/ml in laboratory broth, and by at
least 3 log cfu/ml in artificial saliva supplemented with sucrose. The latter ability is of great
interest as it is closer to the real conditions of contact between S.mutans and its phages. It has
been shown that the combination of saliva, sucrose water and nutrients had synergistic effects
on S.mutans growth and long-term colonization [45]. Based on the results of the current
study, the addition of phages could help in reducing the colonization of teeth surface by S.
mutans. This is particularly true in regard to the ability of ɸAPCM01 to reduce S.mutans bio-
film in a model system after a minimum 24 h of contact. The metabolic activity of the biofilm
was significantly reduced, and the number of live cells decreased by at least 5 log cfu/ml with
phage doses of at least 105 pfu/well. After 48 h of contact with phage, the reduction of the meta-
bolic activity of the biofilm did not systematically come with a reduction in the numbers of
cells, which remained essentially stable. This indicates the prolonged control of the biofilm by
the phage in time. The decrease in the metabolic activity of the biofilm could be due to the
exhaustion of nutrients in the medium even if no significant differences in the control were vis-
ible after 48 h. To accurately explain the metabolic activity of the biofilm multiparametric mea-
surements would need to be used as previously performed for S.mutans biofilms [46]. The
reduction of S.mutans growth and biofilm formation has successfully been tested by the use of
other antimicrobial agents such as essential oils and bioactive fractions [47], bacteriocins [48],
commensal bacteria [49] and probiotic bacteria [50]. Combining these approaches with the use
of phage ɸAPCM01 could compensate for the narrow host range of this phage at the current
stage of investigation, and thus could increase the chances to prevent the development of S.
mutans biofilm and caries formation. The combination of ɸAPCM01 with other S.mutans
phages is also of utmost importance as phage cocktails have proven to be more efficient [51]
because they limit the risk of bacterial adaptation and the emergence of resistance [52]. The
combination of different phages would also permit to extend the host range of the phage cock-
tail and thus would improve its efficiency.
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In conclusion, while the narrow host range is a significant disadvantage, the newly isolated
phage ɸAPCM01 has promising antimicrobial properties, such as the ability to reduce S.
mutans growth and biofilm formation. Its use in combination with other phages and antimi-
crobial agents can now be considered for future potential clinical use.
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